A single center experience on the clinical utility evaluation of an insertable cardiac monitor

Yanhui Li, Teerapat Nantsupawat, Matthew Olson, Venkatakrishna N Tholakanahalli, Selcuk Adabag, Zhong Wang, David G Benditt, Jian-Ming Li

Research output: Contribution to journalArticle

Abstract

Background: The evaluation of insertable cardiac monitor (ICM) has been largely on the device performance and safety with only limited studies on the clinical utility. The aim of this study was to evaluate the clinical utility of ICM in patients with a variety of clinical presentations. Methods: A single-center retrospective study on the clinical utility, as measured by both expected and unexpected clinical useful ICM findings and the initiation of therapeutic interventions, was conducted. Results: Ninety-five consecutive patients (median age 68 years) received ICM Reveal LINQ™ for clinical indications of unexplained syncope (53), cryptogenic stroke (19), unexplained infrequent palpitations (14) and AF management (9). During a median follow-up of 414 days, the causes for unexplained syncope were arrhythmia-related (11.3%), arrhythmia-unrelated (32%) and undetermined (56.6%). Atrial fibrillation in patients with cryptogenic stroke was detected in 31.6% (6/19). The clinical utility occurrence was 48.4% with the expected and incidental (unexpected) clinical utility of 41% and 7.4% patients respectively. Of these, therapeutic interventions based on ICM diagnoses were initiated in 18.9% (18/95) of patients. Conclusions: ICM (Reveal LINQ™) offers substantial expected and unexpected clinical utility in patients with a variety of clinical presentations. The causes of nearly one third of patients receiving ICM for unexplained syncope were unrelated to cardiac arrhythmia. Nearly one fifth of patients with newly diagnosed arrhythmia from ICM received therapeutic interventions.

Original languageEnglish (US)
Pages (from-to)583-587
Number of pages5
JournalJournal of Electrocardiology
Volume51
Issue number4
DOIs
StatePublished - Jul 1 2018

Fingerprint

Cardiac Arrhythmias
Syncope
Stroke
Equipment Safety
Atrial Fibrillation
Therapeutics
Retrospective Studies

Keywords

  • Atrial fibrillation
  • Cardiac arrhythmia
  • Clinical utility
  • Cryptogenic stroke
  • Insertable cardiac monitor
  • Syncope

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Cite this

A single center experience on the clinical utility evaluation of an insertable cardiac monitor. / Li, Yanhui; Nantsupawat, Teerapat; Olson, Matthew; Tholakanahalli, Venkatakrishna N; Adabag, Selcuk; Wang, Zhong; Benditt, David G; Li, Jian-Ming.

In: Journal of Electrocardiology, Vol. 51, No. 4, 01.07.2018, p. 583-587.

Research output: Contribution to journalArticle

@article{8552ae8c92554b789dde05003b1438c7,
title = "A single center experience on the clinical utility evaluation of an insertable cardiac monitor",
abstract = "Background: The evaluation of insertable cardiac monitor (ICM) has been largely on the device performance and safety with only limited studies on the clinical utility. The aim of this study was to evaluate the clinical utility of ICM in patients with a variety of clinical presentations. Methods: A single-center retrospective study on the clinical utility, as measured by both expected and unexpected clinical useful ICM findings and the initiation of therapeutic interventions, was conducted. Results: Ninety-five consecutive patients (median age 68 years) received ICM Reveal LINQ™ for clinical indications of unexplained syncope (53), cryptogenic stroke (19), unexplained infrequent palpitations (14) and AF management (9). During a median follow-up of 414 days, the causes for unexplained syncope were arrhythmia-related (11.3{\%}), arrhythmia-unrelated (32{\%}) and undetermined (56.6{\%}). Atrial fibrillation in patients with cryptogenic stroke was detected in 31.6{\%} (6/19). The clinical utility occurrence was 48.4{\%} with the expected and incidental (unexpected) clinical utility of 41{\%} and 7.4{\%} patients respectively. Of these, therapeutic interventions based on ICM diagnoses were initiated in 18.9{\%} (18/95) of patients. Conclusions: ICM (Reveal LINQ™) offers substantial expected and unexpected clinical utility in patients with a variety of clinical presentations. The causes of nearly one third of patients receiving ICM for unexplained syncope were unrelated to cardiac arrhythmia. Nearly one fifth of patients with newly diagnosed arrhythmia from ICM received therapeutic interventions.",
keywords = "Atrial fibrillation, Cardiac arrhythmia, Clinical utility, Cryptogenic stroke, Insertable cardiac monitor, Syncope",
author = "Yanhui Li and Teerapat Nantsupawat and Matthew Olson and Tholakanahalli, {Venkatakrishna N} and Selcuk Adabag and Zhong Wang and Benditt, {David G} and Jian-Ming Li",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.jelectrocard.2018.05.002",
language = "English (US)",
volume = "51",
pages = "583--587",
journal = "Journal of Electrocardiology",
issn = "0022-0736",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - A single center experience on the clinical utility evaluation of an insertable cardiac monitor

AU - Li, Yanhui

AU - Nantsupawat, Teerapat

AU - Olson, Matthew

AU - Tholakanahalli, Venkatakrishna N

AU - Adabag, Selcuk

AU - Wang, Zhong

AU - Benditt, David G

AU - Li, Jian-Ming

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Background: The evaluation of insertable cardiac monitor (ICM) has been largely on the device performance and safety with only limited studies on the clinical utility. The aim of this study was to evaluate the clinical utility of ICM in patients with a variety of clinical presentations. Methods: A single-center retrospective study on the clinical utility, as measured by both expected and unexpected clinical useful ICM findings and the initiation of therapeutic interventions, was conducted. Results: Ninety-five consecutive patients (median age 68 years) received ICM Reveal LINQ™ for clinical indications of unexplained syncope (53), cryptogenic stroke (19), unexplained infrequent palpitations (14) and AF management (9). During a median follow-up of 414 days, the causes for unexplained syncope were arrhythmia-related (11.3%), arrhythmia-unrelated (32%) and undetermined (56.6%). Atrial fibrillation in patients with cryptogenic stroke was detected in 31.6% (6/19). The clinical utility occurrence was 48.4% with the expected and incidental (unexpected) clinical utility of 41% and 7.4% patients respectively. Of these, therapeutic interventions based on ICM diagnoses were initiated in 18.9% (18/95) of patients. Conclusions: ICM (Reveal LINQ™) offers substantial expected and unexpected clinical utility in patients with a variety of clinical presentations. The causes of nearly one third of patients receiving ICM for unexplained syncope were unrelated to cardiac arrhythmia. Nearly one fifth of patients with newly diagnosed arrhythmia from ICM received therapeutic interventions.

AB - Background: The evaluation of insertable cardiac monitor (ICM) has been largely on the device performance and safety with only limited studies on the clinical utility. The aim of this study was to evaluate the clinical utility of ICM in patients with a variety of clinical presentations. Methods: A single-center retrospective study on the clinical utility, as measured by both expected and unexpected clinical useful ICM findings and the initiation of therapeutic interventions, was conducted. Results: Ninety-five consecutive patients (median age 68 years) received ICM Reveal LINQ™ for clinical indications of unexplained syncope (53), cryptogenic stroke (19), unexplained infrequent palpitations (14) and AF management (9). During a median follow-up of 414 days, the causes for unexplained syncope were arrhythmia-related (11.3%), arrhythmia-unrelated (32%) and undetermined (56.6%). Atrial fibrillation in patients with cryptogenic stroke was detected in 31.6% (6/19). The clinical utility occurrence was 48.4% with the expected and incidental (unexpected) clinical utility of 41% and 7.4% patients respectively. Of these, therapeutic interventions based on ICM diagnoses were initiated in 18.9% (18/95) of patients. Conclusions: ICM (Reveal LINQ™) offers substantial expected and unexpected clinical utility in patients with a variety of clinical presentations. The causes of nearly one third of patients receiving ICM for unexplained syncope were unrelated to cardiac arrhythmia. Nearly one fifth of patients with newly diagnosed arrhythmia from ICM received therapeutic interventions.

KW - Atrial fibrillation

KW - Cardiac arrhythmia

KW - Clinical utility

KW - Cryptogenic stroke

KW - Insertable cardiac monitor

KW - Syncope

UR - http://www.scopus.com/inward/record.url?scp=85047088928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047088928&partnerID=8YFLogxK

U2 - 10.1016/j.jelectrocard.2018.05.002

DO - 10.1016/j.jelectrocard.2018.05.002

M3 - Article

C2 - 29996994

AN - SCOPUS:85047088928

VL - 51

SP - 583

EP - 587

JO - Journal of Electrocardiology

JF - Journal of Electrocardiology

SN - 0022-0736

IS - 4

ER -